These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 12354137)

  • 21. Pharmacokinetic-pharmacodynamic comparison of a novel multiligand somatostatin analog, SOM230, with octreotide in patients with acromegaly.
    Ma P; Wang Y; van der Hoek J; Nedelman J; Schran H; Tran LL; Lamberts SW
    Clin Pharmacol Ther; 2005 Jul; 78(1):69-80. PubMed ID: 16003295
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Acetylcholine does not play a major role in mediating the endocrine responses to ghrelin, a natural ligand of the GH secretagogue receptor, in humans.
    Broglio F; Gottero C; Benso A; Prodam F; Casanueva FF; Dieguez C; van der Lely AJ; Deghenghi R; Arvat E; Ghigo E
    Clin Endocrinol (Oxf); 2003 Jan; 58(1):92-8. PubMed ID: 12519418
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Growth hormone and ghrelin responses to an oral glucose load in adolescent girls with anorexia nervosa and controls.
    Misra M; Miller KK; Herzog DB; Ramaswamy K; Aggarwal A; Almazan C; Neubauer G; Breu J; Klibanski A
    J Clin Endocrinol Metab; 2004 Apr; 89(4):1605-12. PubMed ID: 15070919
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nocturnal ghrelin, ACTH, GH and cortisol secretion after sleep deprivation in humans.
    Schüssler P; Uhr M; Ising M; Weikel JC; Schmid DA; Held K; Mathias S; Steiger A
    Psychoneuroendocrinology; 2006 Sep; 31(8):915-23. PubMed ID: 16814473
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Exercise, hormones, and body temperature. regulation and action of GH during exercise.
    Jørgensen JO; Krag M; Kanaley J; Møller J; Hansen TK; Møller N; Christiansen JS; Orskov H
    J Endocrinol Invest; 2003 Sep; 26(9):838-42. PubMed ID: 14964435
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effect of chronic treatment with octreotide nasal powder on serum levels of growth hormone, insulin-like growth factor I, insulin-like growth factor binding proteins 1 and 3 in acromegalic patients.
    Invitti C; Fatti L; Camboni MG; Porcu L; Danesi L; Delitala G; Cavagnini F
    J Endocrinol Invest; 1996 Sep; 19(8):548-55. PubMed ID: 8905479
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Balance in ghrelin and leptin plasma levels in anorexia nervosa patients and constitutionally thin women.
    Tolle V; Kadem M; Bluet-Pajot MT; Frere D; Foulon C; Bossu C; Dardennes R; Mounier C; Zizzari P; Lang F; Epelbaum J; Estour B
    J Clin Endocrinol Metab; 2003 Jan; 88(1):109-16. PubMed ID: 12519838
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ghrelin potentiates growth hormone secretion driven by putative somatostatin withdrawal and resists inhibition by human corticotropin-releasing hormone.
    Veldhuis JD; Iranmanesh A; Mielke K; Miles JM; Carpenter PC; Bowers CY
    J Clin Endocrinol Metab; 2006 Jun; 91(6):2441-6. PubMed ID: 16537682
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Ghrelin concentrations in acromegalic patients in relation to the administered therapy.
    Wasko R; Jaskula M; Komarowska H; Zamyslowska H; Sowinski J; Waligorska-Stachura J
    Neuro Endocrinol Lett; 2006; 27(1-2):162-8. PubMed ID: 16670671
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ghrelin secretion is inhibited by either somatostatin or cortistatin in humans.
    Broglio F; Koetsveld Pv Pv; Benso A; Gottero C; Prodam F; Papotti M; Muccioli G; Gauna C; Hofland L; Deghenghi R; Arvat E; Van Der Lely AJ; Ghigo E
    J Clin Endocrinol Metab; 2002 Oct; 87(10):4829-32. PubMed ID: 12364482
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Endogenous circulating ghrelin does not mediate growth hormone rhythmicity or response to fasting.
    Avram AM; Jaffe CA; Symons KV; Barkan AL
    J Clin Endocrinol Metab; 2005 May; 90(5):2982-7. PubMed ID: 15713719
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ghrelin test for the assessment of GH status in successfully treated patients with acromegaly.
    Pekic S; Doknic M; Miljic D; Joksimovic M; Glodic J; Djurovic M; Dieguez C; Casanueva F; Popovic V
    Eur J Endocrinol; 2006 May; 154(5):659-66. PubMed ID: 16645012
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical pharmacology of human growth hormone and its secretagogues.
    Root AW; Root MJ
    Curr Drug Targets Immune Endocr Metabol Disord; 2002 Apr; 2(1):27-52. PubMed ID: 12477295
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ghrelin: a hypothalamic GH-releasing factor in domestic fowl (Gallus domesticus).
    Ahmed S; Harvey S
    J Endocrinol; 2002 Jan; 172(1):117-25. PubMed ID: 11786379
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Maintenance of a normal meal-induced decrease in plasma ghrelin levels in children with Prader-Willi syndrome.
    Bizzarri C; Rigamonti AE; Giannone G; Berardinelli R; Cella SG; Cappa M; Müller EE
    Horm Metab Res; 2004 Mar; 36(3):164-9. PubMed ID: 15057669
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The effect of a new slow-release, long-acting somatostatin analogue, lanreotide, in acromegaly.
    al-Maskari M; Gebbie J; Kendall-Taylor P
    Clin Endocrinol (Oxf); 1996 Oct; 45(4):415-21. PubMed ID: 8959079
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of octreotide acetate LAR and lanreotide SR in patients with acromegaly.
    Chanson P; Boerlin V; Ajzenberg C; Bachelot Y; Benito P; Bringer J; Caron P; Charbonnel B; Cortet C; Delemer B; Escobar-Jiménez F; Foubert L; Gaztambide S; Jockenhoevel F; Kuhn JM; Leclere J; Lorcy Y; Perlemuter L; Prestele H; Roger P; Rohmer V; Santen R; Sassolas G; Scherbaum WA; Schopohl J; Torres E; Varela C; Villamil F; Webb SM
    Clin Endocrinol (Oxf); 2000 Nov; 53(5):577-86. PubMed ID: 11106918
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pattern-dependent suppression of growth hormone (GH) pulsatility by ghrelin and GH-releasing peptide-6 in moderately GH-deficient rats.
    Thompson NM; Davies JS; Mode A; Houston PA; Wells T
    Endocrinology; 2003 Nov; 144(11):4859-67. PubMed ID: 12960077
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.